Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
about
Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancerThe After Breast Cancer Pooling Project: rationale, methodology, and breast cancer survivor characteristicsThe clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee.ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferationER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.Biospecimens and biorepositories for the community pathologist.New insights into the role of the immune microenvironment in breast carcinoma.Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast TumorsAssessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer.Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill HER-2 positive human breast cells in vitro via hyperthermia.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition.The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma.Droplet Microfluidic and Magnetic Particles Platform for Cancer Typing.The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer.Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
P2860
Q33786788-E5AB39A5-42B7-41C7-ABEB-413F8060CAEFQ35074445-46891780-08A9-4420-8D56-4E621F75C4E1Q35202536-AA04D9DA-1F13-4FC6-A349-3EBBEFB94117Q35742899-97337C98-6207-45E9-BADF-0E4AD10BE974Q35899955-1B426C38-F30B-4DFF-A89A-D32E0ECC0DDBQ36245537-76184268-CC58-4DD0-92E5-235FB9C09B4CQ36920645-055FE1F1-2208-4AE7-AB9D-7293A8923E71Q36938731-3A9EFE48-5143-4703-B7DF-400FDB15713CQ37119863-43ED953F-0B63-42BA-98AF-B484BCDEC076Q37148669-0DD85D36-16F8-4C02-9637-C498356F5AFEQ37612319-379E3779-FAC4-4B0C-900D-BF5D5008B0BDQ39459376-B13F9C08-CE79-4E09-B321-27CEE4395872Q39564433-69444523-09E5-46DB-8EE9-4439496B0A7EQ40777892-3048C315-0F82-4B79-B7B6-4EAF94834258Q41972324-252858A8-57D0-4C85-9BAD-46D2FDF8A450Q50976709-39B89A6D-A201-403F-8384-7BF97065E99BQ54338174-36F98BE3-DD03-4072-921D-7184BC3F5DD4Q54513997-2D3FE011-0FED-4D14-A206-6D370BCAEDB1
P2860
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@en
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@nl
type
label
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@en
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@nl
prefLabel
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@en
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@nl
P2093
P1476
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
@en
P2093
P356
10.1016/S0305-7372(10)70022-0
P478
36 Suppl 3
P577
2010-11-01T00:00:00Z